Surgery for cancer of the renal pelvis and ureter at Apollo Hospital, Bhat, Gandhinagar · Consultation at Gota OPD, Ahmedabad
When cancer grows in the lining of the kidney’s drainage system or in the ureter, the standard operation removes the kidney, the entire ureter down to the bladder, and a small cuff of the bladder wall around the ureter’s opening. That is more surgery than the tumour appears to need, and families always ask why. The whole drainage lining behaves as one surface, and a stump of ureter left behind is the commonest place for this cancer to return. In carefully selected patients the kidney can be kept instead — decided before the day of surgery, not during it.
Send your CT urography images and biopsy report on WhatsApp · +91-63590-11009
Dr Swati Shah
MS, DrNB (Surgical Oncology)
Kidney Cancer Surgeon · Apollo Hospital, Bhat, Gandhinagar · Gota OPD, Ahmedabad
Shah’s Gastro, Cancer & Robotic Surgery Centre. Trained at high-volume cancer units, qualified in surgical oncology, and in practice long enough to have followed these cancers over years. Google rating 4.99 from 85 reviews at Gota and 5.0 from 28 reviews at Apollo, Bhat.
Upper tract urothelial carcinoma is a cancer of the lining of the urine-collecting system — the renal pelvis inside the kidney, and the ureter, the tube carrying urine down to the bladder. It is a different disease from the kidney cancer most people have heard of, which begins in the kidney’s filtering tissue.
The distinction changes the operation. A cancer in the kidney’s own substance can often be cut out with a rim of normal kidney around it, leaving the rest working. A cancer of the lining cannot, because that lining continues without a break from the renal pelvis, down the ureter, into the bladder — the same cells line all of it, and the same exposure that produced one tumour has bathed the whole surface. That is why Dr Swati Shah looks at the bladder with a cystoscope in every patient before any upper tract operation: it is one field of tissue, not three organs, and it is never assumed to be clean anywhere.
Blood in the urine with no pain at all is the commonest way this cancer announces itself, and also the symptom most easily explained away as a stone or a urine infection. Blood that comes and goes, with no pain and no fever, in an adult over forty, is a reason to examine the upper tract — not a reason to wait and see.
Three investigations decide almost everything, and a plan made without them is a guess.
The first is CT urography — a CT with a delayed phase timed so the contrast fills the drainage system and outlines the tumour. It answers where the tumour is, whether there is one or several, how large, whether it appears to be invading outwards, and whether the lymph nodes are enlarged. Bring the images themselves, not only the report. The second is cystoscopy, in every patient without exception, because a tumour sitting in the bladder changes the whole plan.
The third is a measurement almost nobody is told to expect: kidney function, written down as a number, before surgery. Creatinine and eGFR, and where the other kidney looks less than fully healthy, a nuclear renogram to measure what each kidney actually contributes. This is not a formality. It is the number that decides whether the stronger chemotherapy will be possible after the operation, and it can only be measured beforehand.
Cancer of the upper urinary tract is one of the sentinel cancers of Lynch syndrome, an inherited condition that also raises the risk of bowel, uterine and stomach cancer. Every patient treated here has the tumour tested for mismatch repair proteins, and where that test is abnormal the family is referred for genetic counselling.
Every treatment decision in this disease follows from one classification: low risk or high risk. Low risk requires all of its criteria to be satisfied. High risk needs only one of its features to be present.
| Low risk — every one of these must be true | High risk — any one of these is enough | |
|---|---|---|
| Number of tumours | A single tumour | More than one tumour in the drainage system |
| Size | Smaller than two centimetres | Two centimetres or larger |
| Urine cytology | Low grade | High grade |
| Biopsy at ureteroscopy | Low grade | High grade |
| Appearance on CT urography | No sign of invasion outwards | Invasive appearance, or a blocked and swollen kidney |
| Other factors | — | Unusual histology, or a previous bladder removal for high-grade bladder cancer |
| What is offered | Kidney-sparing treatment as the first choice | Radical nephroureterectomy, with lymph node clearance where the tumour invades the muscle |
The operation removes the kidney, the ureter along its entire length, and a cuff of bladder wall surrounding the point where that ureter enters the bladder — all in one piece, without opening the urinary tract. The bladder cuff is not an optional extra. A retained stump of ureter is the single commonest technical failure in this operation and the commonest site of recurrence afterwards.
The approach depends on the tumour. For disease confined to the kidney and ureter the operation is done laparoscopically or robotically, with the same cancer outcome as open surgery and a faster recovery. Where the tumour is bulky, has grown outside the kidney, or involves large lymph nodes, it is done open — the correct choice rather than a failure, because removing everything in one undisturbed specimen matters more than the size of the incision. Dr Swati Shah states which approach is planned, and what would change it, before the day of surgery.
Two technical points carry real consequences. The ureter is clipped below the tumour early, before the kidney is mobilised, so tumour cells are not washed downstream. And where the tumour has grown into the muscle wall, the lymph nodes are removed to a defined anatomical template on the side the tumour sits, rather than by picking out whichever nodes look abnormal — a template dissection stages the disease accurately and probably treats it, while a random packet of nodes does neither.
One measure that is cheap, effective and routinely forgotten: a single dose of chemotherapy instilled into the bladder in the days after the operation reduces the chance of a new tumour appearing in the bladder later. It is given once the bladder closure is confirmed watertight, and it is part of the operation here rather than an afterthought.
Kidney-sparing treatment is the first choice, not a compromise, for a tumour satisfying every low-risk criterion. It is also offered to anyone for whom removing the kidney would mean dialysis — a single working kidney, tumours on both sides, or kidney function already severely reduced.
How the kidney is spared depends on where the tumour sits. A small tumour inside the renal pelvis or the upper ureter is destroyed with a laser through a fine telescope passed up from the bladder. A tumour in the lower ureter is better dealt with by removing that segment and re-implanting the ureter into the bladder, which also produces a proper specimen for the pathologist. A mid-ureteric tumour can be managed by removing that segment and joining the ends.
Two obligations come with keeping the kidney, and Dr Swati Shah counsels on both before the patient chooses: a second look with the telescope within about eight weeks, which is part of the treatment rather than a check-up, because a single laser session without it is incomplete care; and repeat ureteroscopy under anaesthesia, at intervals, for years. Patients told only that “the kidney can be saved” feel ambushed by the fourth anaesthetic.
Kidney function falls after a kidney is removed — that is arithmetic, not a complication. The consequence patients are rarely warned about is that the fall can take the stronger chemotherapy off the table, because cisplatin needs a certain level of kidney function to be given safely. Many patients who could have had it before the operation can no longer have it afterwards.
Where the tumour has invaded the muscle wall or reached the lymph nodes, chemotherapy after surgery gives a real and substantial improvement in the chance of staying free of disease, and it has to start within about three months of the operation. Put those facts together with the drop in kidney function and you have the single most useful thing this unit does differently: the medical oncologist is involved before the operation, not after it. The pre-operative eGFR is given to them as a number, the likely post-operative figure is estimated, and where it is clear that cisplatin will not be possible afterwards, giving chemotherapy before surgery is discussed at the tumour board. The oncology appointment is booked before discharge rather than left to be arranged from home.
After treatment for an upper tract tumour, new tumours appear in the bladder in a substantial minority of patients, often years later. That is why cystoscopy continues for life, and why “your scan is clear” and “you can stop coming” are not the same sentence.
| When | What happens at that visit |
|---|---|
| Two weeks | Wound check, histology explained in full, kidney function recorded as the new baseline, oncology referral where the tumour invaded muscle or reached the nodes, mismatch repair result discussed |
| Three months | Cystoscopy and urine cytology; kidney function repeated; CT urography for high-risk disease |
| To two years, high risk | Cystoscopy and cytology every three months; CT of chest, abdomen and pelvis with urography every six months |
| Years two to five, high risk | Cystoscopy and cytology every six months; CT urography once a year |
| After kidney-sparing treatment | Second-look ureteroscopy within eight weeks, then ureteroscopy, cystoscopy, cytology and CT urography at three and six months, six-monthly to two years, then yearly, with no end date |
| Every year, for life | Cystoscopy, cytology, imaging of the remaining kidney, and kidney function. Patients with this diagnosis are not discharged |
Two symptoms must never wait for the next appointment: visible blood in the urine, which means a cystoscopy within a fortnight, and persistent pain in the flank on the remaining side, which is never assumed to be left-over pain from the operation.
Some consequences of this operation are not risks to be weighed against benefits. They are certainties, and they are stated before consent rather than discovered afterwards.
The complications that are risks rather than certainties — bleeding needing transfusion, wound infection, clots in the legs or lungs, chest infection, injury to the bowel, spleen or a major blood vessel, urine leaking from the bladder closure, a slow return of bowel function, a collection of lymph fluid after node clearance, a hernia at the incision, a return to theatre, a period of reduced kidney function immediately after surgery, and a small risk to life itself — are each named and explained at the consent discussion, with the individualised figures for the patient in front of her, because age, other illnesses, kidney function and the size of the tumour move every one of them.
What moves the estimate is the approach used, whether a lymph node clearance is part of the operation, how the lower end of the ureter is dealt with, the length of stay, and the room category. Kidney-sparing treatment costs less for the first operation but commits you to repeated procedures under anaesthesia, so the two cannot be compared on a single admission.
Most health insurance policies cover this operation. Cashless admission needs pre-authorisation, raised by the hospital’s insurance desk once the surgery date is fixed — send the policy document and card early, because pre-authorisation for a cancer operation takes longer than for a routine one. Bring the original policy papers, photo identification, and all previous scans on admission. Two costs are commonly missed: mismatch repair testing is billed separately from the histology report, and chemotherapy afterwards is a separate course with its own cost.
★★★★★
“My mother was operated on by Dr. Swati Shah for kidney cancer. We are extremely happy with the treatment and care she received. The surgery went very well, and now my mother is doing fine and recovering well. Dr. Swati Shah is highly skilled, compassionate, and supportive. She explained everything clearly and gave us confidence throughout the treatment. We are very thankful to Dr. Swati Shah and her entire team. Highly recommended for kidney cancer treatment and surgery. Truly one of the best kidney cancer surgeons. 🙏”
Ashok RAJPUROHIT, August 2026
★★★★★
“I operated by Dr swati shah. We came for follow up . And now I am absolutely fine after surgery. Dr swati shah is best kidney cancer surgeon in ahmedabad”
Darji kushal Kushal, August 2026
★★★★★
“One of the best doctor in ahmedabad for uro cancer we have met. Thank u so much mam for everything.. From consultation to surgery, everything was explained thoroughly. Best doctor dor kidney cancer. Highly recommend”
DIVYA PARMAR, November 2025
Because the lining it grew from runs continuously from inside the kidney, down the ureter, into the bladder, and the rest of that lining has had the same exposure — taking only the visible tumour leaves the surface it came from. Where the tumour is genuinely single, small, low grade and not invading, the kidney can be kept, decided on the scan, the cytology and the biopsy before the day of surgery.
No, but it is a reason to be seen now rather than next month. Bleeding that stops does not mean the cause has gone. Bring any scan you have already had, and expect a CT urography and a cystoscopy rather than another course of antibiotics.
Not immediately, and for most patients not at all — one healthy kidney can do the work of two. Function does fall and has to be looked after for life. Where the remaining kidney is already weak, the plan shifts towards keeping the affected kidney if it safely can be.
It can be. Cancer of the upper urinary tract signals Lynch syndrome, which also raises the risk of bowel and uterine cancer. The tumour is tested for mismatch repair proteins in every patient here, and where that is abnormal the family is referred for counselling and screening — which is how relatives get protected rather than diagnosed later.
Yes, for disease confined to the kidney and ureter, with the same cancer outcome as open surgery. Where the tumour is bulky or has spread into the surrounding fat or the nodes, open surgery is right, because removing the specimen in one piece without breaching the urinary tract matters more than the incision.
Consultation at Gota. Surgery at Apollo, Bhat, Gandhinagar.
Swasth Parivar: twice a month, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.
